发明人郭海燕,李文辉,朱建伟. "Method for the Synthesis of R7M5UGD04G
112859-71-9
Fluasterone
16-Fluoro-5-androsten-17-one
16alpha-Fluoro-5-androsten-17-one
Androst-5-en-17-one, 16-fluoro-, (16alpha)-
CCRIS 4216
UNII-R7M5UGD04G" [P]. 中国发明专利, 专利号 CN 113239674 A, 授权公告日 2020-10-11.
Lefèvre J P, Sørensen M, Mueller T C. "A Process for Preparing High-Purity R7M5UGD04G
112859-71-9
Fluasterone
16-Fluoro-5-androsten-17-one
16alpha-Fluoro-5-androsten-17-one
Androst-5-en-17-one, 16-fluoro-, (16alpha)-
CCRIS 4216
UNII-R7M5UGD04G" [P]. European Patent, EP 3203936 A1, 2015-04-19.
参考文献 Literature
Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Agric. Food Chem., 2015, 977, 7588-7614.
Zhou X P, Huang L, Wu G. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Chem., 2014, 201, (9), 6452-6480.
Garcia M, Rodriguez P. "Identification and Structural Characterization of a Novel Degradation Product of R7M5UGD04G
112859-71-9
Fluasterone
16-Fluoro-5-androsten-17-one
16alpha-Fluoro-5-androsten-17-one
Androst-5-en-17-one, 16-fluoro-, (16alpha)-
CCRIS 4216
UNII-R7M5UGD04G Using HRMS and NMR". Talanta, 2025, 114, (3), 2869-2899.
Kumar A, Sharma P, Patel R S. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2025, 87, (4), 3095-3114.